Factor V Has Anticoagulant Activity in Plasma in the Presence of TFPIα: Difference between FV1 and FV2
Peter van Doorn
1
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands
,
Jan Rosing
1
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands
,
Connie Duckers
1
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands
,
Tilman M. Hackeng
1
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands
,
Paolo Simioni
2
Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padua Medical School, Padua, Italy
,
Elisabetta Castoldi
1
Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, The Netherlands
› Author AffiliationsFunding This work was supported by grant 2014–1 from the Dutch Thrombosis Foundation. Prof. Jan Rosing is Van de Laar Professor of Coagulation Enzymology.
Background Activated factor V (FVa) is a potent procoagulant cofactor in the prothrombinase complex, whereas its precursor factor V (FV) stimulates the inhibition of factor Xa (FXa) by tissue factor pathway inhibitor-α (TFPIα), presumably by promoting TFPIα binding to phospholipids. Plasma FV comprises two glycosylation isoforms (FV1 and FV2) with low and high phospholipid-binding affinity, respectively. The FV1/FV2 ratio is increased in carriers of the FV R2 haplotype.
Objective This article demonstrates the TFPIα-cofactor function of FV in plasma and compares FV1 and FV2.
Materials and Methods Thrombin generation at low TF concentration was measured in FV-depleted plasma reconstituted with 0 to 100% FV, FV1 or FV2, and in 122 individuals genotyped for the R2 haplotype. The TFPIα-cofactor activities of FV1 and FV2 were also investigated in a model system of TFPIα-mediated FXa inhibition.
Results In the FV titration, thrombin generation first increased (up to 5% FV) and then progressively decreased at higher FV concentrations. This anticoagulant effect of FV, which was also observed with FV2 but not with FV1, was largely abolished by anti-TFPIα antibodies, suggesting that it reflects TFPIα-cofactor activity of FV. In the model system of TFPIα-mediated FXa inhibition, FV2 was a more potent TFPIα-cofactor than FV1, in line with their respective phospholipid affinities. Accordingly, FV R2 carriers had higher thrombin generation than non-carriers, even after correction for demographics and plasma levels of coagulation factors and inhibitors.
Conclusion FV (and particularly its FV2 isoform) contributes to the TFPIα-dependent down-regulation of thrombin generation in plasma triggered with low TF.
1
Dahlbäck B.
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S. J Thromb Haemost 2017; 15 (07) 1241-1250
4
Rosing J,
Tans G,
Govers-Riemslag JW,
Zwaal RF,
Hemker HC.
The role of phospholipids and factor Va in the prothrombinase complex. J Biol Chem 1980; 255 (01) 274-283
7
Shen L,
Dahlbäck B.
Factor V and protein S as synergistic cofactors to activated protein C in degradation of factor VIIIa. J Biol Chem 1994; 269 (29) 18735-18738
10
Duckers C,
Simioni P,
Spiezia L.
, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood 2008; 112 (09) 3615-3623
12
Peraramelli S,
Thomassen S,
Heinzmann A.
, et al. Role of exosite binding modulators in the inhibition of Fxa by TFPI. Thromb Haemost 2016; 115 (03) 580-590
13
Santamaria S,
Reglińska-Matveyev N,
Gierula M.
, et al. Factor V has an anticoagulant cofactor activity that targets the early phase of coagulation. J Biol Chem 2017; 292 (22) 9335-9344
14
Ndonwi M,
Girard TJ,
Broze Jr GJ.
The C-terminus of tissue factor pathway inhibitor α is required for its interaction with factors V and Va. J Thromb Haemost 2012; 10 (09) 1944-1946
17
Ndonwi M,
Tuley EA,
Broze Jr GJ.
The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010; 116 (08) 1344-1351
18
Hackeng TM,
Seré KM,
Tans G,
Rosing J.
Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 2006; 103 (09) 3106-3111
19
Ndonwi M,
Broze Jr G.
Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 2008; 6 (06) 1044-1046
20
Ahnström J,
Andersson HM,
Hockey V.
, et al. Identification of functionally important residues in TFPI Kunitz domain 3 required for the enhancement of its activity by protein S. Blood 2012; 120 (25) 5059-5062
21
Maurissen LF,
Castoldi E,
Simioni P,
Rosing J,
Hackeng TM.
Thrombin generation-based assays to measure the activity of the TFPI-protein S pathway in plasma from normal and protein S-deficient individuals. J Thromb Haemost 2010; 8 (04) 750-758
22
Rosing J,
Bakker HM,
Thomassen MC,
Hemker HC,
Tans G.
Characterization of two forms of human factor Va with different cofactor activities. J Biol Chem 1993; 268 (28) 21130-21136
23
Nicolaes GA,
Villoutreix BO,
Dahlbäck B.
Partial glycosylation of Asn2181 in human factor V as a cause of molecular and functional heterogeneity. Modulation of glycosylation efficiency by mutagenesis of the consensus sequence for N-linked glycosylation. Biochemistry 1999; 38 (41) 13584-13591
24
Hoekema L,
Nicolaes GA,
Hemker HC,
Tans G,
Rosing J.
Human factor Va1 and factor Va2: properties in the procoagulant and anticoagulant pathways. Biochemistry 1997; 36 (11) 3331-3335
25
Váradi K,
Rosing J,
Tans G,
Pabinger I,
Keil B,
Schwarz HP.
Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation. Thromb Haemost 1996; 76 (02) 208-214
26
Lunghi B,
Iacoviello L,
Gemmati D.
, et al. Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma. Thromb Haemost 1996; 75 (01) 45-48
27
Bernardi F,
Faioni EM,
Castoldi E.
, et al. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997; 90 (04) 1552-1557
28
Castoldi E,
Rosing J,
Girelli D.
, et al. Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma. Thromb Haemost 2000; 83 (03) 362-365
30
Alhenc-Gelas M,
Nicaud V,
Gandrille S.
, et al. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999; 81 (02) 193-197
31
de Visser MC,
Guasch JF,
Kamphuisen PW,
Vos HL,
Rosendaal FR,
Bertina RM.
The HR2 haplotype of factor V: effects on factor V levels, normalized activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000; 83 (04) 577-582
32
Nicolaes GAF,
Tans G,
Thomassen MCLGD.
, et al. Peptide bond cleavages and loss of functional activity during inactivation of factor Va and factor VaR506Q by activated protein C. J Biol Chem 1995; 270 (36) 21158-21166
33
Hemker HC,
Giesen P,
AlDieri R.
, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002; 32 (5-6): 249-253
35
Hackeng TM,
Suijlen DPL,
Hemker HC.
, et al. Thermostable inhibitors of activation of the blood clotting system through contact with foreign surfaces. Google Patents; 2013
36
Segers O,
Simioni P,
Tormene D.
, et al. Genetic modulation of the FV(Leiden)/normal FV ratio and risk of venous thrombosis in factor V Leiden heterozygotes. J Thromb Haemost 2012; 10 (01) 73-80
37
Segers O,
Simioni P,
Tormene D,
Castoldi E.
Influence of single nucleotide polymorphisms on thrombin generation in factor V Leiden heterozygotes. Thromb Haemost 2014; 111 (03) 438-446
39
Dielis AW,
Castoldi E,
Spronk HM.
, et al. Coagulation factors and the protein C system as determinants of thrombin generation in a normal population. J Thromb Haemost 2008; 6 (01) 125-131
40
Castoldi E,
Brugge JM,
Nicolaes GA,
Girelli D,
Tans G,
Rosing J.
Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103 (11) 4173-4179
41
Al Dieri R,
Bloemen S,
Kelchtermans H,
Wagenvoord R,
Hemker HC.
A new regulatory function of activated factor V: inhibition of the activation by tissue factor/factor VII(a) of factor X. J Thromb Haemost 2013; 11 (03) 503-511
42
Suehisa E,
Kawasaki T,
Toku M,
Hidaka Y.
Low level of factor V is associated with development of deep-vein thrombosis in Japanese patients. Thromb Res 2010; 125 (02) 128-133